Lacosamide Injection
Product Images NDC 68083-480

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 68083-480). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gland Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lacosamide-structure (Lacosamide Structure)

Chemical structure diagram of lacosamide, depicting its molecular arrangement with functional groups including an amide, acetamide, and a benzyl moiety, consistent with the active ingredient lacosamide used in injection form.*

FDA Label Image

Lacosamide-carton-label (Lacosamide Carton Label)

Lacosamide Injection, USP 200 mg/20 mL (10 mg/mL) intravenous injection in 10 single-dose vials per carton. The label includes dosage form as 20 mL solution for infusion and specifies intravenous use only. Manufactured by Gland Pharma Limited, Hyderabad, India, with NDC 68083-480-10. Additional text instructs to dispense the enclosed Medication Guide to each patient.*

FDA Label Image

Lacosamide-container-label (Lacosamide Container Label)

Label for Lacosamide Injection, USP 10 mg/mL, showing a total of 200 mg in 20 mL in a single-dose vial. The label states it is for intravenous use only and includes manufacturer information for Gland Pharma Limited, Hyderabad, India. The label also includes dosage instructions, a barcode, and storage warnings.*

FDA Label Image

Lacosamide-figure-1 (Lacosamide Figure 1)

A bar graph titled 'Median Percent Reduction in Seizure Frequency per 28 days from Baseline to the Maintenance Phase by Dose.' It shows three separate studies comparing median percent seizure reduction across placebo and different doses of lacosamide. The vertical axis represents seizure reduction percentage from 0 to 45%. The horizontal axis shows groups labeled placebo and lacosamide with varying doses (200, 400, 600 mg/day). Each study demonstrates higher median percent reductions for lacosamide doses compared to placebo, with some differences marked as statistically significant.*

FDA Label Image

Lacosamide-figure-2 (Lacosamide Figure 2)

A line chart titled 'Proportion of Patients by Responder Rate for Lacosamide and Placebo Groups in Studies 2, 3, and 4.' It displays responder rate (equal to or greater) on the vertical axis from -100% to 100%, with worsening to improvement, and percent of patients on the horizontal axis from 0 to 100. Four lines show responder rates for placebo and three dosage groups of Lacosamide: 200 mg/day, 400 mg/day, and 600 mg/day.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.